NASDAQ NMS - GLOBAL MARKET · MAZE
+1.73% · +$0.5000 · Vol 280.6K
Market closed · last close 4:00 PM ET · price as of 16:01:20 ET
Maze Therapeutics Inc

Maze Therapeutics Inc

Pharmaceuticals
$29.43
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
MAZE
Maze Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is MAZE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading MAZE catalysts
About Maze Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2025
Employees
141
Country
US

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$28.98
Day high
$29.84
Day low
$28.98
Previous close
$28.93
52W high
$51.84
-43.22% from high
52W low
$13.31
42% of range
Market cap
$1.6B
EPS
$-2.6400
Beta
1.01
Shares out
55.5M
Volume
280.6K
0.75× rel vol
Avg volume
373.9K
VWAP
$29.44
Price history computed in-house
1W
+8.28%
1M
+6.32%
3M
+14.16%
1Y
+118.16%
YTD
-28.96%
SMA 50 $28.13 · above
SMA 200 $34.40 · below
52W position 42%

MAZE overview

Veridion Score
59
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around MAZE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading MAZE Form 4 filings
Public disclosures

Congress activity in MAZE

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for MAZE in the cached public ledger.

Federal contracts

MAZE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for MAZE in this window.
Lobbying spend

MAZE lobbying filings, year to date.

Registered lobbying filings matched to Maze Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for MAZE in this window.
Loading news for MAZE
Analyst ratings
Sovereign unlock shows live analyst consensus for MAZE.
Options
Sovereign unlock shows live options positioning for MAZE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.